GlassScriptPhysician profile
Alfred C Burris
NPI 1326039587
$5,235.75
in general payments reported to CMS, 2019-2025
29 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $579 · 2021: $313 · 2022: $528 · 2023: $2,356 · 2024: $416 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809 · Travel and Lodging: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.71 |
| Travel and Lodging | $1,483.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,785.56 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novartis Pharmaceuticals Corporation | $730.40 | 2019-2025 | |
| Pfizer INC. | $341.19 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $316.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $283.45 | 2021-2025 | Verquvo |
| Philips North America LLC | $256.36 | 2020-2025 | (Ck4) Mcot, Ecc Solutions, Extended Holter |
| Medtronic, INC. | $173.99 | 2021-2025 | Linq II, Hawkone, Abre |
| E.R. Squibb & Sons, L.L.C. | $146.81 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $138.37 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $114.97 | 2023-2025 | Opsumit, Uptravi |
| Inari Medical, INC. | $107.19 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ge Healthcare | $95.33 | 2020 | |
| Novo Nordisk INC | $89.60 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $79.98 | 2023-2024 | |
| Abbott Laboratories | $77.79 | 2020-2024 | Diamondback Peripheral |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.24 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $58.98 | 2025 | |
| Hikma Pharmaceuticals USA | $55.84 | 2019-2020 | |
| Shockwave Medical, INC | $50.22 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $49.26 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.07 | 2021-2023 | Lifevest |
| Boston Scientific Corporation | $34.41 | 2019 | |
| Atricure, INC. | $31.70 | 2022 | |
| Cardiovascular Systems INC. | $26.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $15.93 | 2019 | |
| Medtronic Vascular, INC. | $14.12 | 2020 | |
| Amarin Pharma, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Burris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.